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Inhibition of host NOX1 blocks tumor growth and
enhances checkpoint inhibitor–based immunotherapy
Jimmy Stalin1,2 , Sarah Garrido-Urbani1, Freddy Heitz3, Ce´dric Szyndralewiez3, Stephane Jemelin1, Oriana Coquoz2,
Curzio Ruegg2,* , Beat A Imhof1,4,*
NADPH oxidases catalyze the production of reactive oxygen species
and are involved in physio/pathological processes. NOX1 is highly
expressed in colon cancer and promotes tumor growth. To in-
vestigate the efﬁcacy of NOX1 inhibition as an anticancer strategy,
tumors were grown in immunocompetent, immunodeﬁcient, or
NOX1-deﬁcient mice and treated with the novel NOX1-selective in-
hibitor GKT771. GKT771 reduced tumor growth, lymph/angiogenesis,
recruited proinﬂammatory macrophages, and natural killer T lym-
phocytes to the tumor microenvironment. GKT771 treatment was
ineffective in immunodeﬁcient mice bearing tumors regardless of
their NOX-expressing status. Genetic ablation of host NOX1 also
suppressed tumor growth. Combined treatment with the checkpoint
inhibitor anti-PD1 antibody had a greater inhibitory effect on colon
carcinoma growth than each compound alone. In conclusion, GKT771
suppressed tumor growth by inhibiting angiogenesis and enhancing
the recruitment of immune cells. The antitumor activity of GKT771
requires an intact immune system and enhances anti-PD1 antibody
activity. Based on these results, we propose blocking of NOX1 by
GKT771 as a potential novel therapeutic strategy to treat colorectal
cancer, particularly in combination with checkpoint inhibition.
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Introduction
Colorectal carcinoma is the second leading cause of cancer-related
mortality in developed countries (1). Surgical resection is currently
the treatment of choice. However, ~30% of node-positive patients
develop local recurrence or distant metastasis within 5 yr of surgery
and die of the disease (2). Dysregulated expression of proin-
ﬂammatory cytokines and growth factors contributes to the devel-
opment of colorectal tumors and tumor progression by stimulating
tumor angiogenesis and recruiting tumor-promoting immune cells.
The release of proinﬂammatory cytokines in response to surgery
further promotes tumor progression (3). Tumor angiogenesis, that is,
the de novo formation of tumor-associated vessels, is crucial for
tumor progression, whereas in the absence of angiogenesis, tumors
remain dormant as microscopic dormant lesions that can persist for
years (4). In addition to tumor cells, stromal cells and immune cells,
including bonemarrow–derivedmonocytes can induce angiogenesis
through a process called angiogenic switch. This is the result of an
imbalance in the production of pro- versus anti-angiogenic factors,
eventually leading to the sprouting of activated endothelial cells
from the preexisting, quiescent vasculature (5, 6). Many angiogenic
factors (e.g., VEGF and FGF) and their receptors (e.g., VEGFR-2 and FGF-
Rs) have been identiﬁed as therapeutic targets, and inhibitors of
these molecules (e.g., bevacizumab and sunitinib) are currently in
clinical use or under development as novel anti-angiogenic agents to
suppress cancer progression (7).
NADPH oxidases (NOXs) catalyze the production of reactive oxygen
species (ROS). ROS are involved in different physiological and
pathological processes, including cancer, and their effect depends
on concentration and cellular localization (8). The NOX family of
enzymes, which comprises seven isoforms (NOX1, NOX2, NOX3, NOX4,
NOX5, DUOX1, and DUOX2), transports electrons across the cell
membrane during the production of superoxide through the re-
duction of oxygen (9). NOX enzymes play a major role in numerous
cellular processes such as apoptosis, host defense against patho-
gens, intracellular signal transduction, and angiogenesis (10). NOX1,
NOX2, and NOX4 expression in cancer cells promotes tumor growth
and metastasis in several cancers, including melanoma, gastric,
pancreatic, and colon tumors (11). The NOX1 isoform is up-regulated
in colon cancer (12), and its overexpression correlates with in-
ﬂammation rather than tumorigenesis (13, 14). NOX1 is highly
expressed in colon cancer cell lines and promotes proliferation
(15). Small hairpin RNA-mediated NOX1 silencing suppresses tumor
growth in mouse models of colon cancer, and inhibition of NOX
activity with pharmacological pan-NOX inhibitors decreases cancer
cell proliferation without inducing apoptosis (16, 17).
NOX1 is expressed in epithelial cells, pericytes, endothelial cells,
vascular smooth muscle cells, and immune cells (18, 19, 20, 21).
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However, the role of NOX1 in tumor-associated immune cells remains
to be fully characterized. NOX1/2 KO mice show an enhanced
proinﬂammatory macrophage signature and increased frequency of
M1 proinﬂammatory macrophages in tumors growing in these mice
(22). Whether this effect is mediated directly and exclusively by NOX1
remains unclear. Furthermore, in the aortic sinus of diabetic ApoE−/−
mice, NOX1-derived ROS promote macrophage accumulation and
inﬂammation, suggesting that NOX1 modulates macrophage re-
cruitment and may contribute to vascular pathologies (23).
NOX1 is involved in immune-related disorders or immune cell
regulation. NOX1 is up-regulated in blood vessels in an in vivo
model of hypertension and is overexpressed in the atherosclerotic
plaque of patients with cardiovascular diseases or with established
diabetes mellitus (24). These reports are consistent with the ob-
servations that combined inhibition of NOX1 and NOX4 with
pharmacological inhibitors in mice leads to dose-dependent athe-
roprotection (25). Taken together, these ﬁndings suggest that NOX1 is a
promising therapeutic target for the management of immune/
inﬂammatory events in cancer and vascular pathologies.
Here, we show that GKT771, a novel, potent, and highly selective
pharmacological inhibitor of NOX1, or genetic deletion of NOX1 inmice
reduced tumor growth in preclinical models of colorectal cancer and
melanoma in immunocompetent mice. NOX1 inhibition decreased
tumor angiogenesis and lymphangiogenesis and modulated the
composition of tumor-associated immune cells in colorectal cancer
by promoting the recruitment of immune/inﬂammatory cells con-
sistent with the observed decrease in tumor growth. The immu-
nostimulatory function of GKT771 was essential for its antitumor
activity and combination treatment with GKT771, and anti-PD1 anti-
body showed enhanced inhibition of tumor growth.
Results
GKT771 inhibits tumor growth, angiogenesis, and
lymphangiogenesis in MC38-derived colon carcinoma
We and others previously showed that broad-spectrum NOX in-
hibitors targeting several NOX isoforms decrease the growth of ex-
perimental tumors (16, 17). However, because of the lack of speciﬁcity
of the currently available inhibitors, the contribution of each indi-
vidual NOX isoform to tumor growth and progression remains un-
determined. A potent and highly selective NOX1 inhibitor (GKT771) has
been developed by GenKyoTex. As shown in Fig S1A, GKT771 inhibits
NOX1 with an inhibitory constant Ki of 60 ± 6 nM. It is highly selective
over NOX4 (Ki = 4,000 ± 400 nM) and is inactive against all other NOX
isoforms. Moreover, GKT771 shows to be inactive on all counterscreen
assays, including xanthine oxidase, glucose oxidase, and scavenging
assays (data not shown). Together with the availability of NOX1-
deﬁcient mice, GKT771 provides a unique opportunity to investigate
selective NOX1 inhibition as a potential anticancer strategy. To this
end, we used two syngeneic tumor models based on MC38 colon
carcinoma and B16-F10 mouse melanoma subcutaneously trans-
planted into immunocompetent C57/BL6 animals. In these two
models, NOX1 and NOX4 expression was different among the cell
lines and conditions: NOX1 expressionwas higher in B16F10 cells both
in vitro and in vivo, whereas NOX4 expression was higher in MC38
cells in vitro but similar to B16F10 in vivo (Fig S1A and 1B). When tumor
size reached approximately 50mm3, mice were randomly assigned to
ﬁve groups and treated by oral gavage with the NOX1-speciﬁc in-
hibitor GKT771, the broad-spectrum inhibitor GKT831, or the anti–
VEGFR-2 blocking antibody DC101. Treatment with the speciﬁc
inhibitor GKT771 suppressed MC38 and B16-F10 tumor growth com-
pared with vehicle (VL) alone (Figs 1A and B, and S1C). Treatment with
the previously available NOX1/NOX4 inhibitor GKT831 also sup-
pressed B16-F10 tumor growth, whereas it had only a weak effect on
MC38 tumors (Figs 1A and 1B, and S1D). Anti-angiogenic treatment
with the DC101 antibody also decreased tumor growth (Fig 1A).
Because NOXs regulate tumor angiogenesis (13, 15, 24), the number
of blood vascular and lymphatic endothelial cells was quantiﬁed in
tumor cell suspensions by ﬂow cytometry in the CD45-negative cell
fraction using antibodies against CD31 and GP38 (Fig S1E). The GKT771
inhibitor and DC101 antibody reduced the number of CD45−/CD31+/
GP38− blood vascular and CD45−/CD31+/GP38+ lymphatic endothelial
cells (Fig 1C and D). Combined GKT771/DC101 treatment showed
marginal additive effects over treatment with GKT771 alone.
GKT771 inhibits endothelial cell proliferation and angiogenesis
directly and indirectly
Angiogenesis of tumor blood or lymphatic vessels can be inhibited
directly by affecting endothelial cells or indirectly through the
modulation of pro-angiogenic factors produced by tumor cells or
cells of themicroenvironment. To determinewhether NOX1 inhibition
acts via direct or indirect pathways, the effect of GKT771 was ﬁrst
tested using an ex vivo aortic ring angiogenesis assay. Both NOX1 and
dual NOX1/4 inhibitors signiﬁcantly decreased the branching area of
sprouting vessels, a surrogate parameter for angiogenesis (Fig 1E).
This result is consistent with a direct effect on endothelial cells. To
test whether GKT771 also inhibits angiogenesis in vivo, a Matrigel plug
assay was performed by injecting bFGF-loaded Matrigel sub-
cutaneously. At 1 wk after injection, de novo blood vessels were
detected by in vivo staining of blood vessels with FITC-lectin and
monitoring ﬂuorescence in plug sections. Treatment with GKT771
signiﬁcantly decreased the vascularization of plugs (Fig 1F).
To examine the anti-angiogenic mechanism of GKT771, its po-
tential direct effect on endothelial cell proliferation was tested.
Assessment of BrdU incorporation in cultured mouse primary lung
microvascular endothelial cells (mMVEC-L) treated with GKT771
showed signiﬁcant inhibition of cell growth in a concentration-
dependent manner (Fig 1G). To determine whether NOX inhibitors
could block angiogenesis indirectly by decreasing the production of
pro-angiogenic factors, we measured VEGF-A and PLGF (Placental
Growth Factor) levels by ELISA in the plasma of tumor-bearing mice
and in the supernatant of cancer cells treated in vitro with NOX
inhibitors. The results showed that both GKT771 and GKT831 de-
creased the plasma concentration of VEGF-A and PLGF in MC38 and
B16-F10 tumor-bearing mice (Figs 1H and S1F). NOX inhibitors also
decreased the secretion of VEGF-A and PLGF by MC38 and B16-F10
cancer cells in vitro (Fig 1H). DC101 treatment in vivo increased the
levels of both vascular growth factors, consistent with a positive
adaptive response (Fig S1G). Treatment with GKT771 also decreased
the concentration of the lymphangiogenic factor VEGF-C in the
plasma of tumor-bearingmice (Fig 1I). GKT771 and GKT831 signiﬁcantly
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inhibited lymphatic endothelial cell growth in a dose-dependent
manner (Fig 1J) and signiﬁcantly inhibited cell proliferation by ap-
proximately 20% at 10 μM (Fig 1K). The wide-spectrum NOX/DUOX
inhibitor DPI served as a positive control. The inhibitory effects
correlated with an increased number of dead cells (Fig S1H). However,
analysis of VEGF-A mRNA expression in cancer cells treated in vitro
with GKT771 or GKT831 showed no decrease in expression. In contrast,
VEGF-A mRNA measurement in tumors treated in vivo with GKT771
showed a trend towards decreased levels (data not shown). This
suggests that the decrease of VEGF-A in supernatant and mouse
plasma is related to a decreased cell proliferation in vitro and a
decreased tumor growth in vivo.
Taken together, these results indicate that the speciﬁc NOX1 in-
hibitor GKT771 suppressed tumor growth and blocked angiogenesis
and lymphangiogenesis in melanoma and colorectal syngeneic
cancer models. These effects were mediated by decreased pro-
duction of angiogenic factors by cancer cells and direct inhibition of
endothelial cell proliferation and sprouting.
GKT771 inhibits growth of MC38 colon carcinoma and B16F10
melanoma tumors in a clinically relevant model
Starting treatment at 50 mm3 tumor size may overestimate the
potential effects on larger tumors. We, therefore, repeated ex-
periments with GKT771 by starting treatment at tumor sizes of
around 200 mm3, for both MC38 and B16F10 tumor models, which
can be considered more representative of tumors in clinical set-
tings. Mice were treated during 4 d compared with 10 d in the
previous protocol. Under these new experimental conditions, the 4-d
GKT771 treatments inhibited tumor growth (measured as tumor
volume and tumor weight at the end of the experiment) by 35% for
MC38 (Fig 1L and M) and 50% for B16F10 (Fig S1I and J).
These results indicate that GKT771 is efﬁcient in inhibiting growth
of well-established tumors, as it is the case in clinical situations.
NOX1-deﬁcient mice show reduced angiogenesis and do not
respond to GKT771
To determine the involvement of NOX1 endogenously expressed by
host cells in promoting tumor growth, B16-F10 and MC38 cancer
cells were transplanted into wild-type (WT) or NOX1-deﬁcient mice,
followed by treatment with GKT771. Both tumors grew at a slower
rate in NOX1 KO mice compared with WT mice (Figs 2A and S2A).
GKT771 treatment had no additional antitumor effects in NOX1 KO
mice (Figs 2B and S2B).
To conﬁrm the antitumor properties of GKT771, the direct effect
of the compounds on tumor cells was tested in vitro. The two
inhibitors decreased the proliferation of MC38 colon and B16-F10
melanoma cancer cells without affecting cell viability (data not
shown). This was consistent with previous reports showing that
inhibition of NOXs leads to decreased cancer cell proliferation
without inducing apoptosis (17). These results conﬁrmed that
GKT771 is a speciﬁc inhibitor of host NOX1 and displays minor
effects on cancer cell viability.
By contrast, the anti-VEGFR-2 antibody DC101 decreased tumor
growth, and the effect was signiﬁcantly stronger in NOX1-deﬁcient
mice than in WT mice (Fig 2C and D). This suggests that VEGFR-2 and
NOX1 promote tumor growth through different mechanisms of
action. Quantiﬁcation of endothelial cells in MC38 tumors in NOX1-
deﬁcient mice showed signiﬁcantly lower numbers of CD31+GP38−
blood vascular and CD31+GP38+ lymphatic endothelial cells in
NOX1-deﬁcient mice compared with WT mice (Fig 2E).
To directly test the angiogenic potential of host NOX1, an ex vivo
aortic ring assay was performed by comparing the branching area
of rings derived from WT and NOX1-deﬁcient mice treated in vitro
with GKT771 or vehicle only (control DMSO). The results showed that
the branching area of aortic rings was smaller in NOX1-deﬁcient
mice compared with WT mice and GKT771 inhibited the branching
area of aortic rings in WT mice, whereas it had no effect on NOX1-
deﬁcient mice (Fig 2F).
To determine whether the reduced angiogenic potential in
NOX1-deﬁcient mice was caused by a general decrease in the
number of endothelial cells or a speciﬁc angiogenic deﬁcit, we
ﬁrst determined the number of endothelial cells in lungs and
MC38 tumors in WT and NOX1 KO mice by ﬂow cytometry. The
numbers of blood vascular (CD45−/CD31+/GP38−) and lymphatic
endothelial (CD45−/CD31+/GP38+) cells were signiﬁcantly lower in
tumors from NOX1-deﬁcient mice than in those from WT mice.
Such a difference was not observed in the lungs of the same
animals (Figs 2G and H, and S2C and D). The number of CD45+/
CD11b+/F4-80+ activated macrophages in lungs and tumors of
NOX1-deﬁcient and WT mice remained unchanged (Fig 2I).
Figure 1. GKT771 inhibits MC38 colon carcinoma tumor growth by targeting angiogenesis and lymphangiogenesis.
Mice with established MC38 tumors were treated with GKT771 (NOX1 inhibitor, n = 12), GKT831 (NOX1/4 inhibitor, n = 12), DC101 (anti–VEGFR-2 antibody, n = 6), and
the corresponding IgG (n = 9) or vehicle (VI) (n = 14). (A) Tumor size was measured in vivo using a caliper (D-0 to D-15) every 5 d. (B) Tumor size and mass were measured ex
vivo at the end of the experiment at day 15. (C, D) Tumors from each mouse were isolated, and blood vascular endothelial cells (CD45−/CD31+/GP38−) and
lymphatic endothelial cells (CD45−/CD31+/GP38+) were analyzed by ﬂow cytometry. The percentages of blood vascular cells (C) and lymphatic endothelial cells (D) in the
differently treated groups are shown. (E) Aortic rings from C57/BL6 mice were stimulated with mouse rVEGF-A in the presence of GKT771 or GKT831 (1 or 10 μM) and
compared with the vehicle DMSO-treated group as the negative control (n = 7) (0). Images show the rings with vascular branches and the graph shows the results of
quantiﬁcation of the branching area (right). (F) Vascularization in angioreactors as assessed by the FITC-lectin detection system. Mice implanted with angioreactors
premixed with (VL, GKT771) or without (Sham) angiogenic-modulating factors were treated with vehicle (Sham, VL) or GKT771 at 1 and 3 mg/kg/d for 15 d (n = 12).
(G) Inhibition of cell proliferation in VEGF-treatedmMVEC-L cells. Concentration-dependent inhibition of cell proliferation by GKT771 inmMVEC-L cells treated with VEGF (20
ng/ml) for 24 h. Data represent the results from three experiments expressed as the mean ± SD of percentages of the controls (without VEGF treatment). Statistical
analysis was performed using the unpaired t test *P < 0.05. Scale bars were added in the aortic ring images by using Image J software. White scale bar have a size
of 1,000 μm. (H) Plasma of mice bearing MC38 tumors and the supernatants of MC38 cancer cells in culture were collected after GKT771, GKT981, or vehicle
treatment and VEGF-A or PLGF was quantiﬁed by ELISA. (I) Quantiﬁcation of VEGF-C in the plasma of mice bearing MC38 tumors after treatment with GKT771 or vehicle.
(J) Proliferation of lymphatic endothelial LyEnd.1 cells in the presence of graded concentrations of GKT771 or GKT981. (K) Inhibition of LyEnd.1 cell proliferation in
the presence of 10 μM GKT771, 10 μM GKT831, or 10 μM of the broad-spectrum NOX inhibitor DPI. Mice with established MC38 tumors were treated at 200 mm3 with GKT771
(NOX1 inhibitor, n = 10) vehicle (VI) (n = 10). (L, M) Tumor size were measured in vivo using a caliper (D-0 to D-15) (L), and tumor mass was measured ex vivo at the end of the
experiment at day 15 (M).
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Figure 2. NOX1-deﬁcient mice do not respond to GKT771 and exhibit reduced tumor growth, angiogenesis, and lymphangiogenesis.
C57/BL6 and NOX1-deﬁcient mice with established MC38 tumors were treated with GKT771 (n = 11), DC101 (n = 6), rat IgG (n = 6), or vehicle (n = 13). (A, B) Tumor size
was measured in vivo using a caliper (D-0 to D-15) every 5 d. (C, D) Tumor size and mass were measured ex vivo at the end of the experiment. (E) Tumors from C57/BL6
and NOX1-deﬁcient mice were isolated, and blood vascular endothelial cells (CD45−/CD31+/GP38−) and lymphatic endothelial cells (CD45−/CD31+/GP38+) were
analyzed by ﬂow cytometry (n = 13 and n = 11, respectively). The percentages of blood vascular cells and lymphatic endothelial cells in WT and KOmice are shown. (F) Aortic
rings from WT and NOX1-deﬁcient mice were stimulated with mouse rVEGF-A and exposed to GKT771 or DMSO as the negative control (n = 7). Branching areas were
quantiﬁed and graphed. (G–I) Absolute numbers of blood endothelial cells (CD45−/CD31+/GP38−) (G), lymphatic endothelial cells (CD45−/CD31+/GP38+), (H) and
macrophages (CD45+/CD11b+/F4-80+) in lungs and tumors (I) were determined after sorting by cytometry fromWT or KOmice (n = 4). (J–L) Plasma of WT and KOmice bearing
MC38 tumors treated with GKT771 or DMSO was used to quantify VEGF-A (J), PLGF (K), and VEGF-C (L) by ELISA.
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The angiogenic components of the host environment were further
investigated by determining the plasma concentrations of the an-
giogenic factors VEGF-A and PLGF in NOX1-deﬁcient versus WT mice
bearing MC38 or B16F-10 tumors. The results showed that the con-
centrations of both factors were lower in NOX1 KO than in WT tumor
mice. Treatment with GKT771 had no further effect in NOX1-deﬁcient
animals (Figs 2J and K, and S2E). Plasma VEGF-Cwas also decreased in
NOX1-deﬁcient versus WT MC38 tumor-bearing mice (Fig 2L).
Taken together, these results suggest that host NOX1 contributes
to tumor growth, angiogenesis, and lymphangiogenesis. NOX1 de-
ﬁciency affects tumor angiogenesis but not developmental angio-
genesis and macrophages in healthy organs. Therefore, host NOX1
emerges as an attractive target for antitumor treatment.
Host macrophages are not a main target for GKT771 antitumor
effects
The macrophage signatures in NOX1/2 double KO mouse tumors
differ from those in WT mice (22). Although no changes in total
macrophage counts were observed in NOX1 KO animals, considering
their angiogenic potential, we nevertheless investigated whether
GKT771 treatment affected the phenotype of macrophages in tumors.
FACS analysis of CD45+ cells harvested from dissociated MC38
colorectal tumors detected a slight but signiﬁcant increase of MHC
class II+/Ly6C+, type I inﬂammatory macrophages (Fig 3A). DC101
treatment substantially increased the number of inﬂammatory
macrophages in tumors, which nearly doubled in response to
combination treatment with GKT771. However, GKT771 or DC101 alone
or in combination did not affect the ratio of mature (CD45+/CD11b+/
F4-80+) and immature (CD45+/CD11b+/F4-80−) macrophages or the
frequency of total–tumor-associated macrophage (TAM) populations
(CD45+/CD11b+/CD68+/F4-80+ and CD45+/CD11b+/CD68+/F4-80−) (Fig
3B and C).
To determine whether inﬂammatory macrophages are essential
for the antitumor effect of GKT771, the macrophage population was
depleted in C57Bl6/J mice using clodronate liposomes (26).
Clodronate treatment started before the grafting of MC38 carci-
noma cells and continued through the entire experimental period.
When tumors reached 50 mm3 in volume, the mice were treated
with GKT771 or vehicle alone. The results showed that depletion of
macrophages had no effect on the antitumor activity of GKT771 (Fig
3D–F).
These results indicate that NOX1 inhibition increases the
number of MHC class II+/Ly6C+ proinﬂammatory macrophages in
tumors, but this increase is not essential for the antitumor effect
of GKT771.
Figure 3. GKT771 increases proinﬂammatory macrophages in tumors, although they are not essential for its antitumor effect.
(A–C) MC38 tumors from C57/BL6 mice were excised and proinﬂammatory TAM (CD45+/MHC2+/Ly6C+), total macrophages (CD45+/CD11b+/F4/80+), and TAM (CD45+/CD68+/
F4/80+) were stained with the corresponding antibodies and analyzed by ﬂow cytometry (n = 11 for the vehicle, GKT771, and rat IgG groups and n = 6 for DC101 and
DC101+GKT771 groups). The percentages of proinﬂammatory TAM (A), total macrophages (B), and TAM (C) from the differently treated groups of animals are shown.
(D) C57/BL6 mice were treated with clodronate liposomes before tumor cell engraftment. When tumors were established, the mice were treated with GKT771 (n = 10 mice
per group) and the size of tumors was measured with a caliper. (E, F) Tumor size and mass were measured ex vivo at the end of the experiment.
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The immune system contributes to the antitumor effect of GKT771
To determine whether immune system cells other than macro-
phages contribute to the antitumor effect of GKT771, MC38 tumor
growth was examined in immunodeﬁcient NOD SCID Gamma (NSG)
mice. These mice lack T and B lymphocytes and NK cells. GKT771
treatment had a minor and insigniﬁcant antitumor effect in these
animals (Fig 4A and B). To conﬁrm that the antitumor effect of
GKT771 was not directly dependent on NOX1 expression in cancer
cells, we studied the effect of GKT771 on the growth of DLD1 and
LoVo cells, two human colon cancer cell lines expressing different
levels of NOX1 (Fig S3A), grafted onto NSG mice. Although GKT771
treatment did not decrease tumor growth in these immunodeﬁcient
mice (Fig 4C–F), GKT771 suppressed cancer cell growth in vitro (Fig
S3B and C) without inducing cancer cell death (Fig S3D). As shown
for MC38 cells, the effect of GKT771 on DLD1 cell growth was dose
dependent (Fig S3E).
GKT771 treatment decreased the percentage of vascular endo-
thelial cells in DLD1 tumors (Fig 4G), whereas it had no effect on
lymphatic endothelial cells and macrophages (Fig 4H and I). The
total number of endothelial cells in the healthy lungs of NSG tumor-
bearing mice was comparable with that in immunocompetent mice
(Fig 4J–L).
Taken together, these results indicate that the host immune
system contributes substantially to the antitumor effect of GKT771,
whereas effects on angiogenesis and cancer cells do not or only
marginally contribute to decreasing tumor growth in these models.
GKT771 tumor blocking effects depend, at least in part, on
interferon γ activity
The cytokine IFN-γ produced by activated T lymphocytes is essential
for stimulating antitumor immunity (27, 28). We, therefore, in-
vestigated the effect of blocking IFN-γ on the antitumor effect of
GKT771. Immunocompetent, MC38 tumor-bearing mice were treated
with a blocking anti–IFN-γ antibody or GKT771 alone and in com-
bination. Analysis of the kinetics of MC38 tumor growth and tumor
size showed that anti–IFN-γ antibody treatment increased tumor
growth and partially reduced the antitumor effect of GKT771 (Fig 5A
and B). Similar results were obtained using NOX1 KO mice treated
with anti–IFN-γ antibody (Fig 5C).
Taken together, these results demonstrate that the effect of the
NOX1 inhibitor GKT771 on decreasing tumor growth is, at least in
part, dependent on IFN-γ.
GKT771 enhances the antitumor activity of the immune checkpoint
inhibitor anti–PD-1 antibody
Tumors possess the ability to turn off antitumor immunity by
decreasing the recruitment and activation of tumor-inﬁltrating
T-lymphocytes (TILs) and by changing their phenotype (29).
Moreover, anti-angiogenic drugs modulate tumor endothelial cells
by allowing differential inﬁltration and activation of immune cells,
thereby promoting antitumor immunity (30, 31). As NOX1 inhibition
increased tumor inﬁltration by inﬂammatory macrophages, we
tested the effect of GKT771 on TILs and tumor-associated natural
killer T cells (NKT) cells, two cell types with potent antitumor
activities (32, 33). FACS analysis of the effects of GKT771, DC101, and
combination thereof on immune cells inﬁltrating MC38 tumors,
showed that GKT771 treatment did not change the percentages of
CD4+ and CD8+ T cells or B lymphocytes, whereas DC101 antibody
treatment decreased CD4+ and increased CD8+ T cells (Fig 6A–C).
Both compounds increased the percentage of NKT cells when used
as single agents, whereas in combination, they had no additive
effects (Fig 6D).
Checkpoint blockade anti-PD1, anti–PD-L1, and anti-CTLA/4 an-
tibodies promote both CD4+ and CD8+ T cell activation (34). However,
their therapeutic efﬁcacy is often limited, especially when used
alone (35). Their antitumor activity in vivo increases when used in
combination with drugs targeting tumor angiogenesis or other
pathways (30, 31, 36). We, therefore, combined GKT771 tumor
treatment with anti-PD1 antibody. This combination blocked MC38
tumor growth more efﬁciently than GKT771 or anti–PD-1 alone, and
two animals out of seven were rendered completely tumor free (Fig
6E and F).
To determine whether lymphocytes were responsible for the
tumor blocking effect, populations of TILs were analyzed in com-
bined and single drug-treated animals. Compared with GKT771,
anti–PD-1 antibody greatly increased the CD8+ T lymphocyte frac-
tion within TILs, resulting in a relative decrease in the numbers of
CD4+ T lymphocytes. This effect was maintained when anti–PD-1
antibody was combined with GKT771 (Fig 6G and H). In B lympho-
cytes, no relevant differences were detected in response to
monotherapy, whereas combination treatment drastically in-
creased the number of these cells (Fig 6I). Both compounds in-
creased NKT cells when used alone, and the combined treatment
potentiated this effect (Fig 6J). The same potentiating effect was
observed in inﬂammatory macrophages (Fig 6K) despite the effect
of PD-1 antibody treatment on decreasing TAM percentages in
tumors (Fig S4A and B). The potentiating effect of host NOX1 in-
hibition and anti–PD-1 antibody treatment on tumor growth was
conﬁrmed in NOX1-deﬁcient mice treated with anti–PD-1 antibody
(Fig 6L).
In conclusion, combination treatment with a NOX1 inhibitor and
anti-PD1 antibody was more effective for blocking tumor growth
than single agent therapy, and the effect was conﬁrmed in NOX1-
deﬁcient mice. Combined treatment was associated with increased
numbers of B cells, NKT cells, and inﬂammatory macrophages in the
tumor microenvironment.
Discussion
NOX1 and other NOX isoforms are involved in promoting tumor
development (11, 12, 13, 14, 15, 16, 17). However, because NOX in-
hibitors tested in oncological models block several NOX isoforms, it
was difﬁcult to identify the NOXmoleculemost relevant for targeted
tumor treatment. This is important because NOX family members
can compensate for the decreased activity of a speciﬁc isoform, and
this can cause downstream effects that counteract the desired
therapeutic activity, including the induction of invasive phenotypes
through the overexpression of metalloproteases (37). In addition,
broad inhibition of multiple NOX isoforms may cause unwanted
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systemic effects by reducing ROS production in cells of the innate
immune system, leading to increased susceptibility to infectious
diseases. One example is defective NOX2 leading to chronic
granulomatous disease (38). To prevent these damaging effects, we
developed a novel NOX1 inhibitor called GKT771, which possesses an
excellent combination of selectivity and potency. Pharmacological
Figure 4. The antitumor effect of GKT771 is suppressed in immunodeﬁcient mice.
(A) Immunodeﬁcient NSG mice with established MC38 mouse colorectal tumors were treated with GKT771 or vehicle (n = 7). Tumor sizes were measured in vivo with
a caliper during the course of the experiment. (B) MC38 tumor size and mass were measured ex vivo at the end of the experiment. (C) Immunodeﬁcient NSG mice
with established human LoVo colorectal tumors were treated with GKT771 or vehicle (n = 8 per group) (C). (D) NSG mice with established human DLD1 colorectal tumors
were treated with GKT771 (n = 21), GKT831 (n = 14), or vehicle (n = 19) (D). Tumor sizes were measured in vivo by a caliper during the course of the experiment. (E, F) Tumor
size and mass were measured ex vivo at the end of the experiment. (G–I) Tumors from NSG mice bearing DLD1 colorectal tumors were isolated and blood vascular
endothelial cells (CD45−/CD31+/GP38−), lymphatic endothelial cells (CD45−/CD31+/GP38+), andmacrophages (CD45+/CD11b+/F4/80+) were analyzed by ﬂow cytometry (n = 19
for the vehicle group and n = 21 for the GKT771 group). The percentages of blood vascular cells, lymphatic endothelial cells, and macrophages in GKT771 or vehicle
treated mice are shown. (J–L) Absolute numbers of blood endothelial cells, lymphatic endothelial cells, and macrophages in the lungs and tumors from C57/BL6 and NSG
mice analyzed by ﬂow cytometry (n = 5).
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in vitro assays using cell membranes and whole cell lysates con-
ﬁrmed that GKT771 blocks the activity of NOX1 without interfering
with other NOX isoforms.
In this work, we investigated the efﬁcacy of this novel compound
in two experimental mouse tumor models. A colon carcinoma
model was used because NOX1 is expressed at low level in normal
colon epithelial cells and is highly up-regulated in colon adeno-
carcinoma, which, therefore, represents an ideal tumor target for
colorectal cancer treatment (12). In addition, we used a melanoma
model because melanoma cells tend to express low levels of NOX1
(data not shown) and may not respond to NOX1 inhibition. Col-
lectively, we showed that NOX1 inhibition had potent antitumor
effects in both models, and this effect was dependent on an intact
immune system and required the inhibition of host NOX1.
The ﬁrst important ﬁnding of the present work is that tumor NOX1
is not critical for the overall in vivo antitumor effects of GKT771. This
is an unexpected result, as NOX1 gene silencing experiments
demonstrated that NOX1 promotes colorectal carcinoma cell
proliferation and cell cycle progression leading to increased tumor
growth (15, 17, 39). In line with these results, in vitro treatment of
cancer cells with GKT771 reduced tumor cell growth and cell cycle
progression. However, the in vivo antitumor effect of GKT771 was not
related to the presence or absence of NOX1 expression in cancer
cells (i.e., DLD1 and LoVo cells). Rather, it was dependent on host
NOX1 expression. Importantly, tissue expression of NOX1 in colon
carcinoma patients has no prognostic value regarding survival (40).
The observations that the therapeutic effects of GKT771 are dis-
sociated from NOX1 expression levels in cancer cells seems at odd
with previously published data. For this apparent discrepancy, we
have no deﬁnitive explanation. However, there is a major difference
between the experimental setting of these experiments: we acutely
inhibited NOX1 function with a drug in established tumors, whereas
the reported experiments were performed by injecting cancer cells
with constitutively silenced NOX1 expression. The latter conditions
may be more stringent than ours but does not reﬂect the clinical
conditions in which treated tumors are already well established. We
will address this issue in future experiments, for example, with
pharmacokinetics studies in tumormodels. Indeed, it will be of interest
to determine the amount of GKT771 present in tumors and healthy
tissues/organs to assess its biodistribution and tumor penetration.
NOX1 inhibition in tumor cells in vitro decreased the production
of VEGF-A and PLGF, two important angiogenic factors associated
with tumor growth and progression (41, 42). We did not observe any
inhibitory effect of GKT771 on VEGF-A mRNA expression levels,
suggesting that the decreased VEGF-A secretion by cells in vitro due
to NOX1 inhibition may involve post-translational regulation, such
as proteinmaturation, transport, and secretion, or could be due to a
decrease in cell number. However, although GKT771 reduced the
plasma concentrations of PLGF and VEGF-A and suppressed blood
vessel and lymphatic angiogenesis, this was not the main mech-
anism by which NOX1 suppressed tumor growth. NOX1-deﬁcient
mice showed reduced tumor angiogenesis, thereby validating the
effects observed with pharmacological NOX1 inhibition but still
supported tumor growth. GKT771 may inhibit angiogenesis through
a dual mechanism: directly by suppressing endothelial pro-
liferation and sprouting, and indirectly by affecting angiogenic
factor production. The latter mechanism is supported by previous
work showing that NOX1 activity contributes to VEGF-A expression
and secretion. However, assessment of the effect of GKT771 in
immunodeﬁcientmice showed that despite signiﬁcantly decreasing
tumor angiogenesis (Fig 4J), GKT771 treatment was not effective at
reducing tumor growth (Fig 4E–F). Thus, the anti-angiogenic effect
of GKT771 is not sufﬁcient to explain the global antitumor effects of
NOX1 inhibition. This is the second important conclusion of our
work. In parallel with the effects on angiogenesis, GKT771 decreased
tumor lymphangiogenesis and reduced the concentration of the
lymphatic growth factor VEGF-C in the plasma of tumor-bearing
mice. A small, insigniﬁcant reduction of tumor lymphangiogenesis
was observed in NOX1-deﬁcient mice, suggesting the involvement
of tumor-derived and NOX1-regulated factors. The lack of an
Figure 5. The antitumor effect of NOX1 inhibition partially depends on IFN-γ.
Mice with established MC38 tumors treated with GKT771, an anti–IFN-γ antibody, or combination thereof and the corresponding controls (n = 6/8 mice per group)
are shown. (A) Tumor size was measured in vivo with a caliper during the course of the experiment. (B) Tumor size measured ex vivo at the end of the experiment.
(C) C57/BL6 WT and NOX1-deﬁcient mice with established MC38 tumors were treated with anti–IFN-γ antibody or the corresponding IgG (n = 8 mice per group). Tumor
size was measured ex vivo at the end of the experiment.
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Figure 6. GKT771 increases the efﬁcacy of anti–PD-1 antibody immunotherapy in MC38 colorectal carcinoma.
(A–D) MC38 tumors of C57/BL6 mice were isolated, stained with the indicated antibodies, and analyzed by ﬂow cytometry. (A–D) CD4+ and CD8 T+ lymphocytes
([CD4+/CD3+/CD45+] or [CD8+/CD3+/CD45+]), (C) B lymphocytes (CD45+/CD3−/B220+), and (D) NKT cells (CD45+/CD3+/NK1.1+). The percentages of cells in the differently
treated groups are shown. (E, F) Mice with established MC38 tumors were treated with GKT771 (n = 6), anti-PD1 antibody (n = 7), combinations thereof (n = 6), or the
corresponding controls (n = 8) are shown. (E, F) Tumor size was measured in vivo with a caliper during the experiment. (G) Tumor size was measured ex vivo at the end of
the experiment. (G–K) Tumors were isolated, and the percentages of CD4+ T lymphocytes (G), CD8+ T lymphocytes (H), B lymphocytes (I), NKT cells (NKT) (J),
and proinﬂammatory macrophages (K) were determined by ﬂow cytometry. C57/BL6 WT and NOX1-deﬁcient mice with established MC38 tumors were treated with anti-PD1
antibody or the corresponding IgG (n = 6/8 mice per group). (L) Tumor size was measured ex vivo at the end of the experiment (L).
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additional GKT771 effect on angiogenesis in NOX1-deﬁcient mice
conﬁrmed the speciﬁcity of GKT771 for NOX1 and supported that
NOX1 expressed by host cells constitutes a major target of GKT771.
As tumor angiogenesis and lymphangiogenesis are important local
events that promote regional and systemic dissemination (43, 44),
in future studies, it will be important to test whether these effects of
GKT771 translate into reduced regional and distant metastases.
The third important ﬁnding of this study is that the antitumor
effect of NOX1 requires an intact immune system. Host immune
cells in tumors contribute to antitumor effects in many types of
tumors (45). In contrast to the antitumor effect observed in the
immunocompetent syngeneic murine model, GKT771 had no anti-
tumor effects in immunodeﬁcient mice bearing human or mouse
CRCs. This suggests that the immune system provides an essential
contribution to the antitumor effects of NOX1 inhibitors. NOX1 is
expressed by various immune cell populations, including macro-
phages and lymphocytes (46). In addition, numerous inﬂammatory
cytokines such as INF-γ affect the expression levels of NOX1, and
INF-γ itself is involved in the recruitment of hemopoietic cells (47),
suggesting that NOX1 contributes to immune cell recruitment in the
tumor microenvironment. Macrophages are among the immune
cells whose phenotype is regulated by NOX1 expression. Double
deletion of NOX1 and NOX2 induces polarization of macrophages
towards the M1 proinﬂammatory phenotype (22). However, whether
deletion of NOX1 alone is sufﬁcient to induce M1 polarization re-
mains unclear. To investigate this hypothesis, we used different
cellular markers to quantify the number of total macrophages
(CD11b+/F4-80+), TAMs (CD11b+/CD68+/F4-80+), or proinﬂammatory,
M1 like macrophages (MHC II+/Ly6C+) in tumors treated with GKT771
or tumors growing in NOX1-deﬁcient mice. Interestingly, our results
showed that blocking NOX1 increased the number of proin-
ﬂammatory macrophages in the tumors. This effect was also ob-
served by genetic deletion of NOX1 in the host. In addition to its
effect on macrophages, GKT771 increased the number of NKT cells
inﬁltrating the tumor. This ﬁnding is interesting as NKT cells have
antitumor activity and can activate immune cells, particularly,
CD8+/CD4+ T and B lymphocytes, TAMs, and also NK cells (32). Of
further interest is the fact that combined GKT771 and DC101
treatment increased CD8+ T cell recruitment to the tumor. The
critical role of the immune system in the GKT771 antitumor activity is
further supported by the observation that blocking IFN-γ with a
monoclonal antibody partially reduced the efﬁcacy of GKT771
therapy. This is consistent with the previously reported correlation
between NOX1 and IFN-γ expression in colon epithelial cells (28).
The fourth important result was that blocking the T-cell
checkpoint inhibitor PD-1 with an anti-PD1 antibody in combination
with GKT771 enhanced the antitumor activity of these compounds as
single agents. Such combinatorial use of the anti-PD1 antibody with
other antitumor drugs targeting different molecular mechanisms
was reported for other therapeutic compounds. For example, anti-
PD1 treatment combined with anti–angiopoietin-2 or anti-CSF1
antibodies suppresses tumor development in several mouse
models (48, 49). It will be of clinical relevance to test whether
tumors refractory to anti-PD1 therapy may be sensitized by NOX1
inhibition.
In conclusion, we showed that blocking NOX1 with the novel
small-molecule inhibitor GKT771 inhibits tumor growth in mice. We
showed that host NOX1 is critical for this effect. Stimulation of the
innate immune system, in particular, proinﬂammatory macro-
phages and NKT cells, and inhibition of angiogenesis and lym-
phangiogenesis are events associated with the antitumor activity of
GKT771. As the antitumor effects of GKT771 requires an intact im-
mune system, we propose that GKT771 elicit immunomodulatory
effects essential for its antitumor activity. Consistent with this
notion, combination of GKT771 with the immune cell checkpoint
inhibitor anti-PD1 resulted in a mutual enhancement of the anti-
tumor activity of each single agent. NOX1 inhibition, alone or in
combination with checkpoint inhibitors, may, therefore, represent a
promising antitumor strategy in colorectal cancer (Fig 7).
Materials and Methods
Inhibitors
GKT771 and GKT831 NOX inhibitors were developed by GenKyoTex
S.A. using recombinant cells transfected with the NOX1 to NOX5
isoforms. Activity of compounds against the different NOX isoforms
was measured as previously described (50). Brieﬂy, membranes
prepared from the different recombinant cell lines were incubated
in PBS with Amplex Red, HRP, and appropriate cofactors. ROS
production was induced by the addition of NADPH. Inhibitory ac-
tivity of compounds was measured in the presence of increasing
concentrations ranging from 1 nM to 100 μM. After 20 min of in-
cubation at 37°C, ROS levels were measured using a BMG Labtech
microplate reader.
Cell culture
Mouse primary lung microvascular endothelial cells (mMVEC-L)
were grown in complete mouse endothelial cell medium using a
kit (M1168-Kit; Cell Biologics). Human dermal lymphatic endothelial
cells were grown in Endothelial Cell Growth Medium from Pro-
moCell. Human colon cancer cell lines SW620 (CVCL_0547), DLD1
(CVCL_0248), Caco-2 (CVCL_0025), and LoVo (CVCL_0399) were cul-
tured in DMEM (Life Technologies) supplemented with FCS (10%), PS
(1%), L-glutamine (1%), and sodium pyruvate (1%). Mouse immor-
talized lymphatic endothelial cells (LyEnd.1), mouse melanoma
cancer cell lines B16-F10 (CVCL_0159), and B16-F0 (CVCL_0604) and
the mouse colorectal cancer cell line MC38 (CVCL_B288) were
cultured in DMEM (Life Technologies) supplemented with FCS (10%),
PS (1%), L-glutamine (1%), and sodium pyruvate (1%). The cells were
grown in a humidiﬁed atmosphere with 5% CO2 at 37°C. Absence of
mycoplasma contamination from the different cell lines used
during the experiments was performed by using the PCR myco-
plasma Test Kit I/C (PromoCell).
BrdU incorporation assay
mMVEC-L cells were treated with DMSO as vehicle or GKT771 for 1 h
at 37°C. Cells were stimulated or not with recombinant murine VEGF
(Catalog No. 450-32 – Lot #010899; Peprotech) at 20 ng/ml for 24 h at
37°C.
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The cells were then labeled with BrdU for 2 h at 37°C, after which
the medium was removed and the cells were ﬁxed by addition of
FixDenat solution for 30 min at room temperature. After FixDenat
removal, the cells were incubated with anti–BrdU-POD for 1.5 h at
room temperature. The cells were then washed three times for
5 min at room temperature, incubated with the substrate for 3 min at
room temperature on a shaker, and chemiluminescence was mea-
sured using a ﬂuorimeter within 10 min after adding the reagent.
Cell proliferation assay
Cells (106) were plated in six-well plates overnight followed by drug
exposure for different time periods. Adherent cells were detached
from the plate using trypsin, followed by addition of PBS without
Ca2+/Mg2+. Suspended cells were centrifuged at 1,500 rpm for 5 min
by using AWEL centrifuge (C48) and swing out rotor (SO400), and
resuspended in PBS/10% FCS before counting. Dead and living cells
were counted with the Countess II FL Automated Cell Counter
(Thermo Fisher Scientiﬁc) after adding trypan blue.
ELISA
VEGF-A, VEGF-C, and PLGF measurement in platelet-diminished
plasma was performed using mouse blood subjected to two
steps of centrifugation (3,500 rpm for 15 min) and cell culture
supernatant prepared using one centrifugation step (10,000 rpm for
10 min). ELISA was performed using the mouse VEGF-A/mouse PLGF
DuoSet ELISA (R&D Systems) or the mouse VEGF-C ELISA kit from
CusaBio following the manufacturer’s protocols.
Quantitative polymerase chain reaction
Cell line and tumor RNA was extracted using the RNeasy Mini kit
(QIAGEN) according to the supplier’s instructions. The extracted
RNA was assayed using NanoDrop at 260 nm (Thermo Fisher Sci-
entiﬁc). RT was performed by adding 1 μg of RNA to 10 μl of amixture
(RT buffer DNX 25×, 100 mM; RT random primers 10×; MultiScribe
Reverse Transcriptase; and H2O [Applied Biosystems]). RT was
performed in a thermocycler at 25°C for 10min, 37°C for 2 h, 85°C for
5 min, and then 4°C. cDNA (50 ng/μl) was mixed with 24 μl of a
mixture of SYBR Green (Agilent, Stratagene), right and left primers,
and H2O. PCR was then performed using the Stratagene Mx 3000 Pro
QPCR (Agilent Technologies) according to the following proﬁle: one
cycle of 10 min at 95°C, and then 40 cycles of 30 s at 95°C and 1 min
at 60°C. The results were analyzed using MxPro software (Stra-
tagene). Human GAPDH (NM_002046.3; AB Applied Biosystems) was
used as an internal control. The qRT-PCR were routinely performed
with two technical replicates and three biological replicates. The
qRT-PCR data were presented as delta Ct values of the investigated
genes relative to GADPH.
Animal procedures
C57Bl6-J immunocompetent and NSG immunodeﬁcient (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mice were purchased from The Jackson
Laboratory and bred in-house. NOX1-deﬁcient mice (B6.129X1-
Nox1tm1Kkr/J) were purchased from The Jackson Laboratory. All
animal procedures were performed in accordance with the In-
stitutional Ethical Committee of Animal Care in Geneva and the
Swiss Cantonal Veterinary Ofﬁce (Authorization numbers: Ge93/14
and Ge17/16). Male and female mice between 5 and 7 wk were used.
Mouse aortic ring assay
The thoracic aorta was dissected from 6–8-wk-old C57BL/6 mice,
NSG mice, and NOX1 KO mice (51). Adipose tissue surrounding the
aorta was removed. After the cleaning step, the aortas were cut into
0.5-mmwide rings with a scalpel, and the rings were then incubated
in serum-free OptiMEM (Life Technologies) overnight at 37°C in 5%
CO2. The next day, the rings were embedded in 1 mg/ml type I
collagen (Millipore) and maintained at 37°C in a 5% CO2, 95% hu-
midity incubator in OptiMEM supplemented with 2.5% FCS, 100 U/ml
penicillin/streptomycin, and 30 ng/ml VEGF165 (Peprotech). Aortic
rings were cultured in the presence of the different NOX inhibitors
(GKT771 and GKT831). Microvessel outgrowth was imaged daily by
phase-contrast microscopy (ImageXpress; Molecular Devices) and
subsequently quantiﬁed with MetaMorph (Molecular Devices). The
nonsprouting fragments were excluded from the quantiﬁcation.
Tumor growth studies
Mouse and human tumors were produced by subcutaneous in-
jection of tumor cells diluted in PBS (1 × 106 for DLD1, 5 × 105 for
MC38, and 1 × 106 for B16-F10 and LoVo). When tumors reached 50 or
200 mm3 depending of the experiments, the mice were subjected to
intraperitoneal administration of puriﬁed antibodies twice per
week at a dose of 600 μg per injection per mouse for DC101; gavage
twice daily for the NOX1 inhibitor GKT771 at 10 mg/kg, or once daily
for the NOX1/4 inhibitor GKT831 at 20 mg/kg; or Vehicle (VL) (i.e.,
methylcellulose and Tween 80) until the mice were euthanized.
Tumor size was measured with a caliper and tumor volume was
determined according to the following equation: (length × width ×
thickness) × 0.5236. Tumor size and mass were also evaluated ex
vivo at the end of the experiment after the animals were eutha-
nized. Before being euthanized, the animals were anesthetized with
a mix of ketamine and xylasizne (80 mg/kg and 10 mg/kg, re-
spectively) before intratracheal instillation of 10% formalin to ﬁx
tumors and organs. After parafﬁn embedding, the samples were cut
into sections at ﬁve distinct levels. For ﬂow cytometry analysis,
tumors were removed without ﬁxation with PFA.
Figure 7. Schematic model proposed for the impact of NOX1 and NOX1-combined treatments on tumor host cell composition.
The composition in tumor-associated host blood vessels, lymphatic vessels, and immune cells of nontreated tumors and corresponding treated tumors is represented.
The amount of tumor-associated blood and lymphatic vessels is decreased in treated tumors compared with nontreated tumors. The inﬁltration of proinﬂammatory
and antitumor immune cells is increased in NOX1, VEGFR-2, and PD-1 monotherapy treatedtumors. These effects are more pronounced in NOX1/VEGFR-2 and
NOX1/PD-1 combined therapy compared with each treatment alone and nontreated tumors.
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All therapeutic monoclonal antibodies (mAbs), including anti-
mouse PD-1 (clone RMPI-14 IgG2a; 10 mg/kg) and anti–IFN-γ (clone
XMG1.2 IgG1; 10 mg/kg), were obtained from BioXCell and admin-
istered two times per week.
Macrophage depletion in tumors was achieved by injection of
mice with clodronate liposomes two times per week. Clodronate
liposomes and control liposomes were obtained from
LIPOSOMA.
Flow cytometry
After dissection, the tumors and lungs were cut with razor blades
and digested using gentleMACS Dissociators with the corre-
sponding mouse and human dissociation kit from Miltenyi Biotec
following the manufacturer’s protocols. Single-cell suspensions for
both tumor and lung samples were obtained by straining through a
70-μm mesh ﬁlter, and the cells were washed twice in FACS buffer
(PBS/Fetal Calf Serum 5%/5 mM EDTA). The cells were incubated
with ﬂuorescent antibodies for 30 min at 4°C to prevent Fc receptor
binding and washed once with FACS buffer. Then, the cells were
stained with the indicated ﬂuorophore-conjugated antibodies and
analyzed using the Gallios ﬂow cytometer (Beckman Coulter) or
sorted with the FACSARIA II ﬂow cytometer (BD).
In vivo angiogenesis assay
Angiogenesis was assessed in male C57BL/6 mice (20–22 g) ordered
fromElevage Janvier. Angioreactors ordered from Amsbio (directed in
vivo angiogenesis assay ref 3450-048-K) were prepared according to
the kit instructions. Brieﬂy, implant-grade silicone cylinders closed at
one end, called angioreactors, are ﬁlled with 20 μl of Trevigen’s
PathClear basement membrane extract premixed with or without
angiogenic-modulating factors. A mix of VEGF (10 μg) and FGF (50 μg)
obtained from PeproTech was used. Two angioreactors per mouse
were then implanted subcutaneously in the dorsal ﬂank of mice. At
the onset of angiogenesis, vascular endothelial cells grow into the
basementmembrane extract and formvessels in the angioreactor. As
early as 15 d postimplantation, there were enough cells to determine
an effective dose response to angiogenic-modulating factors using
an FITC-lectin detection system. Micewere treatedwith GKT771 by oral
gavage (10 ml/kg/d) from D-0 to D-14.
Statistical analysis and expression of results
Data were expressed as mean values ± SEM of the indicated
number of experiments. Statistical analysis was performed with
Prism software (GraphPad Software Inc.). The variance between
different groups was estimated before statistical analysis. When
comparing more than two groups, nonparametric one-way ANOVA
followed by Dunn’s multiple comparison test was used. Signiﬁcant
differences between two groups were determined using the un-
paired t test or Mann–Whitney test. A P-value ≤0.05 was consid-
ered signiﬁcant. In animal studies, the investigator was blinded to
the group allocation and mice were distributed at random into
separate groups.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201800265.
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